Novavax (NVAX) Total Current Liabilities (2010 - 2026)

Novavax's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $342.5 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 18.88% year-over-year to $342.5 million in Q1 2026; TTM through Mar 2026 was $342.5 million, a 18.88% decrease from a year earlier, with the FY2025 full-year figure at $460.0 million, down 60.16% from the prior year.
• Total Current Liabilities slipped to $342.5 million in Q1 2026 per NVAX's latest filing, from $460.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $2.5 billion in Q4 2022 and bottomed at $342.5 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $1.2 billion (2024), against an average of $1.3 billion.
• Across the five-year window, Total Current Liabilities surged 87.08% in 2022 and tumbled 66.39% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $2.5 billion in 2022, then slumped by 33.53% to $1.6 billion in 2023, then retreated by 29.4% to $1.2 billion in 2024, then slumped by 60.16% to $460.0 million in 2025, then declined by 25.54% to $342.5 million in 2026.
• Per Business Quant, the three latest NVAX Total Current Liabilities figures stand at $342.5 million (Q1 2026), $460.0 million (Q4 2025), and $429.9 million (Q3 2025).